Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1

被引:9
|
作者
Lesosky, Maia [1 ,2 ]
Rangaka, Molebogeng X. [2 ,3 ,4 ]
Pienaar, Cara [1 ]
Coussens, Anna K. [2 ,5 ]
Goliath, Rene [2 ]
Mathee, Shaheed [6 ]
Mwansa-Kambafwile, Judith [2 ,9 ,10 ]
Maartens, Gary [3 ]
Wilkinson, Robert J. [2 ,3 ,7 ,8 ]
Wilkinson, Katalin Andrea [2 ,3 ,8 ]
机构
[1] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Observatory, South Africa
[2] Univ Cape Town, Wellcome Ctr Infect Dis Res Africa, Inst Infect Dis & Mol Med, Observatory, South Africa
[3] Univ Cape Town, Dept Med, Fac Hlth Sci, Observatory, South Africa
[4] UCL, Inst Global Hlth, Fac Populat Hlth Sci, London, England
[5] Univ Cape Town, Dept Pathol, Fac Hlth Sci, Observatory, South Africa
[6] Site B Khayelitsha Community Hlth Ctr, Western Cape Dept Hlth, Cape Town, South Africa
[7] Imperial Coll London, Dept Med, London, England
[8] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England
[9] Univ Witwatersrand, Natl Inst Communicable Dis, Ctr TB, Johannesburg, South Africa
[10] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
基金
英国惠康基金;
关键词
tuberculosis; HIV-1; predictive; plasma; biomarker; ANTIRETROVIRAL THERAPY; INFECTION; GAMMA;
D O I
10.1093/cid/ciy823
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1-infected individuals are likely to progress to active disease is unknown. Methods. Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1-infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. Results. Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1 alpha, transforming growth factor-alpha (TGF-alpha). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-gamma were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. Conclusions. Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.
引用
收藏
页码:295 / 305
页数:11
相关论文
共 50 条
  • [1] Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
    McPherson, Tristan D.
    Sobieszczyk, Magdalena E.
    Markowitz, Martin
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 413 - 420
  • [2] Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain
    Lamers, Susanna L.
    Salemi, Marco
    Galligan, Derek C.
    Morris, Alanna
    Gray, Rebecca
    Fogel, Gary
    Zhao, Li
    McGrath, Michael S.
    JOURNAL OF NEUROVIROLOGY, 2010, 16 (03) : 230 - 241
  • [3] Human Immunodeficiency Virus-Associated Tuberculosis
    Wilkinson, Katalin A.
    Schwander, Stephan
    Torok, M. Estee
    Meintjes, Graeme
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2011,
  • [4] Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the "Juice Worth the Squeeze?"
    Cohen, Myron S.
    Eron, Joseph J., Jr.
    SEXUALLY TRANSMITTED DISEASES, 2011, 38 (05) : 410 - 412
  • [5] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE
    TYAGI, SC
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (05): : 309 - 315
  • [6] Triclustering method for finding biomarkers in human immunodeficiency virus-1 gene expression data
    Siswantining, Titin
    Bustamam, Alhadi
    Sarwinda, Devvi
    Soemartojo, Saskya Mary
    Latief, Moh. Abdul
    Octaria, Elke Annisa
    Siregar, Anggrainy Togi Marito
    Septa, Oon
    Al-Ash, Herley Shaori
    Saputra, Noval
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2022, 19 (07) : 6743 - 6763
  • [7] Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages
    Szaniawski, Matthew A.
    Spivak, Adam M.
    Bosque, Alberto
    Planelles, Vicente
    JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (05) : 777 - 785
  • [8] Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis
    Walker, Naomi F.
    Schutz, Charlotte
    Ward, Amy
    Barr, David
    Opondo, Charles
    Shey, Muki
    Elkington, Paul T.
    Wilkinson, Katalin A.
    Wilkinson, Robert J.
    Meintjes, Graeme
    JOURNAL OF INFECTIOUS DISEASES, 2024, 231 (01) : 109 - 114
  • [9] Current Antiretroviral Therapies and Future Trends in Management of Human Immunodeficiency Virus-1 Infection
    Bulteel, Naomi S.
    Leen, Clifford
    ERCIYES MEDICAL JOURNAL, 2019, 41 (01) : 5 - 11
  • [10] Genetic diversity of human immunodeficiency virus-1 isolates in Parana, Brazil
    Michelon Toledo, Paula Virginia
    de Carvalho, Denisc Siqueira
    de Rossi, Silvia Gomes
    Brindeiro, Rodrigo
    de Queiroz-Telles, Flavio
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (03) : 230 - 236